

Supplementary Table 3. Factors associated with unfavourable outcome (mRS 3-6) at 3-months follow up (univariate analysis; follow-up imaging cohort)

	OR (95 % CI)	<i>P</i> value
Age (year)	1.08 (1.02-1.14)	0.005
Female sex	1.58 (0.76-3.30)	0.22
Concomitant platelet inhibition	1.09 (0.31-3.78)	0.90
Medical history		
Ischaemic stroke/TIA	1.41 (0.68-2.94)	0.36
Atrial fibrillation	0.59 (0.15-2.33)	0.46
Hypertension	4.71 (1.28-17.28)	0.020
Hyperlipidemia	1.29 (0.60-2.76)	0.51
Diabetes mellitus	3.27 (1.48-7.24)	0.004
Heart failure	2.04 (0.88-4.73)	0.097
Peripheral vascular disease	1.68 (0.43-6.62)	0.46
Renal function: GFR < 60 mL/min	2.13 (0.98-4.66)	0.058
CHA ₂ DS ₂ VASc score*	1.57 (1.21-2.03)	0.001
HAS-BLED score [†]	1.91 (1.17-3.11)	0.010
Modified Rankin scale score [†]		
Pre stroke	2.29 (1.54-3.39)	< 0.001
At admission	2.60 (1.85-3.65)	< 0.001
NIHSS at admission [§]	1.29 (1.15-1.45)	< 0.001
ASPECTS at admission	0.51 (0.34-0.76)	0.001
Infarct size		
Small	Ref.	0.001
Medium	1.36 (0.46-3.98)	
Large anterior or posterior	5.88 (2.26-15.26)	
Time since last intake NOAC	1.00 (0.95-1.05)	0.99
Time to first scan since onset [∥]	1.00 (1.00-1.00)	0.66
Haemorrhagic transformation	3.08 (1.07-8.88)	0.038

^{*}CHA₂DS₂VASc score, range 0-9, from low to high risk of ischaemic stroke in atrial fibrillation; †HAS-BLED score, range 0-9, from low to high risk of Haemorrhage under oral anticoagulation.; †Modified Rankin scale score, from 0 (no symptoms) to 6 (death); *NIHSS, stroke related neurological deficits, from 0 (no symptoms) to 42; "Excluding cases with unknown onset.